11 19

Patients and methods: Between December 2019 and May 2021, a total of 30 male patients (mean age: 41.7±3.2 years; range, 33 to 45 years) who underwent CABG with at least one SVG were included in the study. Saphenous veins were harvested using the open technique and stored at room temperature in either DuraGraft® or heparinized saline. At one-year follow-up, symptomatic patients underwent coronary computed tomography angiography (CTA). The patients were divided into two groups based on their admission dates. Those who received the DuraGraft® were assigned to the intervention group (Group 1, n=14), while patients who received heparinized normal saline solution were assigned to the control group (Group 2, n=16). A total of 67 grafts from 30 patients were analyzed.

Results: One-year angiographic evaluations showed no significant difference in graft patency between the two groups (p>0.05). There was no significant difference in segmental diameter reduction (p=0.483). However, venous wall thickening was significantly less in the DuraGraft® group, whereas diffuse wall thickening was observed in the control group (p=0.020).

Conclusion: The reduction in venous wall thickening in the DuraGraft® group in our study suggests a possible long-term benefit. However, due to the lack of extended follow-up data, these findings should be interpreted with caution.